Affluence and Private Health Insurance Influence Treatment and Survival in Non-Hodgkin's Lymphoma

PLoS One. 2016 Dec 19;11(12):e0168684. doi: 10.1371/journal.pone.0168684. eCollection 2016.

Abstract

Background: The aim of this study was to investigate inequalities in survival for non-Hodgkin's lymphoma (NHL), distinguishing between direct and indirect effects of patient, social and process-of-care factors.

Methods: All cases of NHL diagnosed in Ireland in 2004-2008 were included. Variables describing patient, cancer, stage and process of care were included in a discrete-time model of survival using Structural Equation Modelling software.

Results: Emergency admissions were more common in patients with co-morbid conditions or with more aggressive cancers, and less frequent for patients from more affluent areas. Aggressive morphology, female sex, emergency admission, increasing age, comorbidity, treatment in a high caseload hospital and late stage were associated with increased hazard of mortality. Private patients had a reduced hazard of mortality, mediated by systemic therapy, admission to high caseload hospitals and fewer emergency admissions.

Discussion: The higher rate of emergency presentation, and consequent poorer survival, of uninsured patients, suggests they face barriers to early presentation. Social, educational and cultural factors may also discourage disadvantaged patients from consulting with early symptoms of NHL. Non-insured patients, who present later and have more emergency admissions would benefit from better access to diagnostic services. Older patients remain disadvantaged by sub-optimal treatment, treatment in non-specialist centres and emergency admission.

MeSH terms

  • Age Factors
  • Aged
  • Aged, 80 and over
  • Disease-Free Survival
  • Female
  • Hospitalization*
  • Humans
  • Insurance, Health*
  • Ireland
  • Lymphoma, Non-Hodgkin / mortality*
  • Lymphoma, Non-Hodgkin / therapy*
  • Male
  • Middle Aged
  • Registries
  • Sex Factors
  • Survival Rate

Grants and funding

The National Cancer Registry is funded by the Department of Health. Additional funding for this study was provided by Irish Cancer Society grant H1COM12. There was no additional external source of funding for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.